IMD-1828

Phase Ia Dose Escalation Phase Primary Objectives: 1. To evaluate the safety and tolerability of IMD1828 in participants with advanced solid tumors. 2. To determine the maximum tolerated dose (MTD) and/or recommended dose extension (RDE) of IMD1828. Secondary Objectives: 1. To evaluate the pharmacokinetic characteristics of IMD1828. 2. To evaluate the immunogenicity of IMD1828. 3. To evaluate the preliminary antitumor activity of IMD1828. Exploratory Objectives: 1. To explore the biomarkers of leigluzi in tumors and the tumor microenvironment. 2. To explore the biomarkers of CLDN 6 in tumors. Phase Ib Dose Extension Phase and Phase II Dose Optimization Phase Primary Objectives: 1. To further evaluate the safety and tolerability of IMD1828. 2. To evaluate the preliminary antitumor activity of IMD1828 in specific tumor types. Secondary objectives: 1. To confirm the PK characterization of IMD1828. 2. To assess the immunogenicity of IMD1828. 3. To further evaluate the efficacy of IMD1828. Exploratory objective: To explore the association between the expression of leigluzi and/or CLDN 6 biomarkers and clinical efficacy.